Ticagrelor 274693-27-5: Advanced Antiplatelet for Cardiovascular Health
Revolutionizing cardiovascular care with a potent P2Y12 inhibitor to prevent heart attacks and strokes.
Get a Quote & SampleProduct Core Value
Ticagrelor 274693-27-5
Ticagrelor (CAS 274693-27-5) is a critical pharmaceutical active ingredient, acting as a reversible P2Y12 receptor antagonist. Its primary function is to inhibit platelet aggregation, a key factor in the formation of blood clots that can lead to serious cardiovascular events.
- Learn about the ticagrelor antiplatelet mechanism and how it effectively prevents thrombotic events.
- Discover the efficacy of ticagrelor for cardiovascular event prevention in patients with acute coronary syndrome.
- Understand the potential ticagrelor side effects and how they are managed.
- Explore critical ticagrelor drug interactions to ensure safe and effective use.
Key Advantages
Enhanced Platelet Inhibition
Ticagrelor provides potent inhibition of platelet aggregation by targeting the P2Y12 receptor, contributing significantly to acute coronary syndrome management.
Dual Cardiovascular Protection
It is instrumental in heart attack prevention and stroke prevention, especially in patients with established cardiovascular disease or those who have undergone stent placement.
Advanced Pharmacological Profile
As a P2Y12 inhibitor, its reversible binding and metabolic pathway offer distinct advantages in clinical application and patient management.
Key Applications
Cardiovascular Disease Prevention
Essential in reducing the risk of heart attack and stroke in patients with coronary artery disease, a key aspect of ticagrelor cardiovascular event prevention.
Antiplatelet Therapy
A cornerstone treatment in antiplatelet therapy, directly impacting patient outcomes in critical cardiovascular scenarios.
Acute Coronary Syndrome Treatment
Crucial for patients experiencing ACS, where its rapid action and efficacy are vital for managing critical cardiac events.
Stent Thrombosis Prevention
Significantly lowers the risk of blood clot formation within coronary stents, a critical consideration after percutaneous coronary intervention.